Symphogen

Symphogen is developing recombinant polyclonal antibody therapeutics.

History:

Founded in 2000.

Acquisitions:
Receptor BioLogix (2009; technology only)

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
Europe

Research Focus:
Disease Therapeutics-Research Therapeutics-Development Therapeutics-Clinical early (I, II)

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: